After 30 Years, A Flexible Chemo Port Aims to Reshape Patient Care

MIAMI, FL – June 22, 2026 – In a move that signals a potential paradigm shift in long-term vascular access, PorTal Access, Inc. today announced it has received FDA clearance for its FLEXI-PORT™ family of implantable ports. The clearance introduces a device that directly challenges the decades-old design standards for chemotherapy ports, promising significant improvements in patient comfort and procedural flexibility for clinicians.

For patients undergoing long-term treatments like chemotherapy, the implantable port is a life-sustaining gateway. Yet, for decades, the technology has remained largely static: a rigid port body implanted under the skin. PorTal Access is making a bold claim: that its flexible, versatile system is the “first true innovation in chemo ports in over 30 years.” With this regulatory green light, the company now faces the challenge of turning that innovation into a new standard of care.

Redefining the Patient Experience

At the heart of the FLEXI-PORT™ innovation is a focus on the human impact of a medical implant. Traditional ports, made of rigid materials like titanium or hard plastic, can be a source of chronic discomfort, limiting movement and serving as a constant, physical reminder of a patient's condition. PorTal Access’s core design feature—a flexible port body that requires a smaller incision—directly addresses this long-standing issue.

This isn't merely a creature comfort; it's a strategic intervention in the patient's journey. The psychological burden of long-term treatment is immense, and any innovation that can reduce physical discomfort and improve cosmetic outcomes can have an outsized impact on a patient's quality of life. An interventional radiologist familiar with the technology, who wished to remain anonymous, noted that design considerations related to aesthetics and comfort can have a profound impact on a patient's emotional well-being. By creating a device that is less obtrusive and more integrated with the body, PorTal Access is acknowledging that the patient experience is a critical, and often overlooked, component of effective care.

The system is cleared for both adult and pediatric patients, a crucial detail that underscores its potential breadth of impact. For children, in particular, a more comfortable and less noticeable device could be transformative, reducing the fear and anxiety associated with their treatment regimens.

Disrupting a Stagnant Market

The claim of being the “first true innovation in 30 years” is a powerful marketing statement, but it also reflects a widely held perception within the clinical community. While the market, dominated by giants like BD and AngioDynamics, has seen incremental improvements—such as power-injectable capabilities for CT scans and catheters with anti-thrombogenic coatings—the fundamental design of the port itself has seen little evolution.

PorTal Access appears to have identified a deep, unmet need. The most compelling evidence for this is not in its technology, but in its funding structure. According to the company, over 85% of its financing came from physicians who place these ports or refer patients for them. This level of grassroots financial backing from end-users is rare in the medical device industry and serves as a powerful validation of the product's potential. It suggests that the clinicians on the front lines have been waiting for a better solution and are willing to invest their own capital to make it a reality.

“This is the first true innovation in chemo ports in over 30 years,” said Angela Dotson, COO & Head of Business Development of PorTal Access. “FLEXI-PORT™ is truly a game changer for every patient and any clinician who places it.” The company’s strategy hinges on convincing the healthcare market that the limitations of rigid ports are no longer an acceptable trade-off for reliable vascular access.

A New Era of Clinical Versatility

Beyond patient comfort, FLEXI-PORT™ is engineered to solve critical logistical challenges for healthcare providers. The system is designed for implantation in either the chest or the arm and is available in both 5Fr and 6Fr catheter sizes. This built-in versatility gives clinicians unprecedented flexibility to tailor the procedure to the individual patient.

For instance, a patient with breast cancer who has had lymph nodes removed may not be a suitable candidate for a standard chest port on the affected side. An easy-to-implant arm port provides a vital alternative. Similarly, anatomical variations or prior surgeries can make traditional placements difficult. By offering a single product family that addresses multiple implantation scenarios, PorTal Access aims to simplify inventory for hospitals and streamline the procedural workflow for interventional radiologists and surgeons.

“From the beginning, our vision has been to rethink chemotherapy port placement through technologies that improve the experience for both patients and providers,” stated Dr. Michael Tal, Founder and CEO of PorTal Access. This dual focus is key to the company’s strategy. A device that is better for patients is a strong selling point, but a device that is also easier, faster, or more versatile for clinicians to use is what drives adoption in busy healthcare systems.

From Vision to Commercial Reality

With FDA clearance secured, PorTal Access now pivots from development to execution. “This milestone marks the transition from building to scaling,” commented Dotson, acknowledging the significant road ahead. The company plans to roll out commercialization efforts, comprehensive clinician training programs, and strategic collaborations with healthcare systems across the United States.

Breaking into a market with deeply entrenched competitors and established hospital contracts will be a formidable challenge. Success will depend not only on the clinical superiority of FLEXI-PORT™ but also on PorTal Access’s ability to effectively train providers, demonstrate economic value to hospital administrators, and build a robust supply chain.

The company's physician-centric approach, which was instrumental in its funding, will likely be a cornerstone of its market-entry strategy. Peer-to-peer education and advocacy are powerful drivers of change in medicine. As the first cohort of clinicians begins to use FLEXI-PORT™, their experiences will be critical in determining whether this flexible device can permanently reshape the rigid landscape of vascular access.